252
Views
1
CrossRef citations to date
0
Altmetric
Case Report

A 3-year-old child with multi-drug resistant epilepsy responding to pharmacological and nonpharmacological treatments

&
Pages 322-326 | Received 23 Dec 2020, Accepted 08 Apr 2021, Published online: 25 May 2022

References

  • Geerts A, Arts WF, Stroink H, et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Childhood. Epilepsia. 2010;51(7):1189–1197.
  • Berg AT, Rychlik K. The course of childhood-onset epilepsy over the first two decades: a prospective, longitudinal study. Epilepsia. 2015;56(1):40–48.
  • Ji T, Yang Z, Liu Q, et al. Vagus nerve stimulation for pediatric patients with intractable epilepsy between 3 and 6 years of age: study protocol for a double-blind, randomized control trial. Trials. 2019;20(1):44.
  • Sheth RD, Stafstrom CE. Intractable pediatric epilepsy: vagal nerve stimulation and the ketogenic diet. Neurol Clin. 2002;20(4):1183–1194.
  • Tzadok M, Harush A, Nissenkorn A, et al. Clinical outcomes of closed-loop vagal nerve stimulation in patients with refractory epilepsy. Seizure. 2019;71:140–144.
  • Majkowska-Zwolińska B, Zwoliński P, Roszkowski M, et al. Long-term results of vagus nerve stimulation in children and adolescents with drug-resistant epilepsy. Childs Nerv Syst. 2012;28(4):621–628.
  • Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav. 2011;20(1):57–63.
  • Orosz I, McCormick D, Zamponi N, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia. 2014;55(10):1576–1584.
  • Kossoff EH, Pyzik PL, Rubenstein JE, et al. Combined ketogenic diet and vagus nerve stimulation: rational polytherapy?Epilepsia. 2007;48(1):77–81.
  • Devinsky O, Nabbout R, Miller I, et al. Long-term ­cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019;60(2):294–302.
  • Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014 Mar 5;2014(3):CD009270
  • Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34(3):229–241.
  • Lattanzi S, Brigo F, Cagnetti C, et al. Efficacy and safety of adjunctive cannabidiol in patients with lennox-gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;32(10):905–916.
  • Treat L, Chapman KE, Colborn KL, et al. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58(1):123–127.
  • Masataka Y, Takumi I, Maa E, et al. Report of a 6-month-old Asian infant with early infantile epileptic encephalopathy whose seizures were eliminated by cannabidiol. Epilepsy Behav Rep. 2020;14(100373):1–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.